Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations.
M. B. Cervera-Sánchez, Daniel San-Juan, Roberto Díaz-peregrino, E. Z. Camacho-Castillo, Sthefany Anahi Bringas-Ortiz, Christian Padilla-Cabezutd
British Journal of Clinical Pharmacology July 21, 2026 DOI: 10.1002/bcp.70690 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Psilocybin Serotonin |
| Key findings | Preclinical models suggest psilocybin may confer antiseizure effects through 5-HT2A activation, and clinical evidence shows no increased seizure risk under medical supervision, but conflicting evidence and high-dose concerns urge caution. |
Abstract
Psilocybin shows potential in neuropsychiatric disorders but has a complex relationship with epilepsy and seizures. We reviewed literature up to November 2025 to identify studies relevant to psilocybin's effects on seizures and epilepsy, including our research on serotonergic modulation. Core studies addressing the research question and supplementary mechanistic evidence were included for synthesis. Risk of bias (RoB) was assessed by study type; independent reviewers achieved strong agreement (unweighted Cohen's κ = 0.80, SE = 0.185; 99% CI 0.006-0.011; per cent agreement = 88.9%). Experimental models suggest psilocybin, through 5-hydroxytryptamine receptor 2A (5-T2A) activation, may confer antiseizure effects. Preclinical data support serotonergic modulation as a promising strategy. RoB assessment highlighted methodological challenges, suggesting cautious interpretation. Clinical evidence in neuropsychiatric populations shows no increased seizure risk under medical supervision. Psilocybin could serve as an adjunctive therapy via selective serotonergic modulation. However, conflicting evidence and concerns at high doses urge caution. Future animal studies and clinical trials must confirm psilocybin's safety and efficacy in the treatment of epilepsy.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cites 14
- Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology May 20, 2016
- Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants Clinical Pharmacology & Therapeutics December 12, 2022
- Psychedelics. Current Biology 2022
- Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016 Journal of Psychopharmacology September 5, 2018
- Drug–drug interactions involving classic psychedelics: A systematic review Journal of Psychopharmacology November 20, 2023
and 9 more in the library